Equities

Jiangsu Lianhuan Pharmaceutical Co Ltd

600513:SHH

Jiangsu Lianhuan Pharmaceutical Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)8.07
  • Today's Change-0.01 / -0.12%
  • Shares traded1.78m
  • 1 Year change-17.06%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of CNY
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments250309323
Total Receivables, Net616591535
Total Inventory315279203
Prepaid expenses140168134
Other current assets, total31227.79
Total current assets1,3531,3691,202
Property, plant & equipment, net1,1621,033870
Goodwill, net212121
Intangibles, net139126119
Long term investments194.976.76
Note receivable - long term------
Other long term assets------
Total assets2,8562,7152,355
LIABILITIES
Accounts payable181152165
Accrued expenses475442
Notes payable/short-term debt690642522
Current portion long-term debt/capital leases31494.17
Other current liabilities, total296346285
Total current liabilities1,2471,2441,017
Total long term debt835050
Total debt804741576
Deferred income tax4.435.013.93
Minority interest163147123
Other liabilities, total4.532.722.71
Total liabilities1,5021,4481,197
SHAREHOLDERS EQUITY
Common stock285287288
Additional paid-in capital260269269
Retained earnings (accumulated deficit)809717612
Treasury stock - common--(6.51)(10)
Unrealized gain (loss)(0.2)----
Other equity, total------
Total equity1,3541,2671,158
Total liabilities & shareholders' equity2,8562,7152,355
Total common shares outstanding285285285
Treasury shares - common primary issue01.692.53
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.